Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “TTR-mediated Amyloidosis”

44 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 44 results

Early research (Phase 1)Study completedNCT01814839
What this trial is testing

A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC (Revusiran) in Healthy Volunteers

Who this might be right for
TTR-mediated Amyloidosis
Alnylam Pharmaceuticals 85
Large-scale testing (Phase 3)Looking for participantsNCT06672237
What this trial is testing

NTLA-2001 in ATTRv-PN

Who this might be right for
Neuromuscular DiseaseNeuromuscular Diseases (NMD)Neurodegenerative Disease+17 more
Intellia Therapeutics 60
Not applicableStudy completedNCT04201418
What this trial is testing

Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation

Who this might be right for
Hereditary Transthyretin-mediated (ATTRv) AmyloidosisPolyneuropathy
Alnylam Pharmaceuticals 67
Not applicableActive Not RecruitingNCT05873868
What this trial is testing

Myocardial Effects in Patients With ATTRv With Polyneuropathy Treated With Patisiran or Vutrisiran

Who this might be right for
Transthyretin AmyloidosisAmyloidosis, Hereditary
Rennes University Hospital 20
Large-scale testing (Phase 3)Enrolling By InvitationNCT06679946
What this trial is testing

Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Who this might be right for
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Alnylam Pharmaceuticals 700
Not applicableActive Not RecruitingNCT06073574
What this trial is testing

CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study

Who this might be right for
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Ionis Pharmaceuticals, Inc. 150
Large-scale testing (Phase 3)WithdrawnNCT04418024
What this trial is testing

Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneurophathy

Who this might be right for
Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
Eidos Therapeutics, a BridgeBio company
Early research (Phase 1)Study completedNCT05661916
What this trial is testing

Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects

Who this might be right for
Transthyretin-Mediated Amyloidosis
Alnylam Pharmaceuticals 96
Early research (Phase 1)Study completedNCT02797847
What this trial is testing

A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects

Who this might be right for
Transthyretin-mediated Amyloidosis (ATTR Amyloidosis)
Alnylam Pharmaceuticals 80
Not applicableApproved For MarketingNCT02939820
What this trial is testing

Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)

Who this might be right for
TTR-mediated AmyloidosisAmyloidosis, HereditaryAmyloid Neuropathies, Familial+3 more
Alnylam Pharmaceuticals
Large-scale testing (Phase 3)Looking for participantsNCT07223203
What this trial is testing

TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

Who this might be right for
Hereditary Transthyretin-Mediated Amyloidosis With PolyneuropathyhATTR-PN
Alnylam Pharmaceuticals 125
Early research (Phase 1)Study completedNCT01559077
What this trial is testing

Trial to Evaluate Safety, Tolerability, and Parmacokinetics of ALN-TTR02 in Healthy Volunteer Subjects

Who this might be right for
TTR-mediated Amyloidosis
Alnylam Pharmaceuticals 17
Large-scale testing (Phase 3)Study completedNCT01960348
What this trial is testing

APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis

Who this might be right for
TTR-mediated AmyloidosisAmyloidosis, HereditaryAmyloid Neuropathies, Familial+3 more
Alnylam Pharmaceuticals 225
Post-approval studies (Phase 4)Looking for participantsNCT05489523
What this trial is testing

Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation

Who this might be right for
Transthyretin Cardiac Amyloidosis
University of Texas Southwestern Medical Center 25
Very early researchWithdrawnNCT04569903
What this trial is testing

Evaluation of a Claims-based Algorithm for the Identification of Transthyretin-mediated Amyloidosis (ATTR) Amyloidosis in Medical Records

Who this might be right for
Transthyretin Amyloidosis
Yale University
Large-scale testing (Phase 3)Study completedNCT02510261
What this trial is testing

The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)

Who this might be right for
Amyloidosis
Alnylam Pharmaceuticals 211
Not applicableActive Not RecruitingNCT06073587
What this trial is testing

The CARDIO-TTRansform Scintigraphy Sub-study

Who this might be right for
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Ionis Pharmaceuticals, Inc. 150
Testing effectiveness (Phase 2)Study completedNCT02292186
What this trial is testing

A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

Who this might be right for
TTR-mediated Amyloidosis
Alnylam Pharmaceuticals 25
Not applicableLooking for participantsNCT06360289
What this trial is testing

Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of the Transthyretin (TTR) Variants and Patients With Hereditary Transthyretin-mediated (hATTR) Amyloidosis With Polyneuropathy

Who this might be right for
Hereditary Amyloidosis, Transthyretin-RelatedAsymptomatic Carrier State
Alnylam Pharmaceuticals 500
Testing effectiveness (Phase 2)Study completedNCT01981837
What this trial is testing

Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

Who this might be right for
TTR-mediated Amyloidosis
Alnylam Pharmaceuticals 26
Load More Results